Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010–2019)

Oritavancin displayed potent and stable activity (MIC(90) range of 0.06 to 0.5 mg/L) over a 10-year period (2010 to 2019) against Gram-positive pathogens that cause bloodstream infections (BSI), including methicillin-resistant Staphylococcus aureus (MRSA) and resistant subsets of Enterococcus spp. D...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvalhaes, Cecilia G., Sader, Helio S., Streit, Jennifer M., Castanheira, Mariana, Mendes, Rodrigo E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Epidemiology and Surveillance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846398/
https://www.ncbi.nlm.nih.gov/pubmed/34807761
http://dx.doi.org/10.1128/AAC.01667-21
Descripción
Sumario:Oritavancin displayed potent and stable activity (MIC(90) range of 0.06 to 0.5 mg/L) over a 10-year period (2010 to 2019) against Gram-positive pathogens that cause bloodstream infections (BSI), including methicillin-resistant Staphylococcus aureus (MRSA) and resistant subsets of Enterococcus spp. Daptomycin and linezolid were also active against methicillin-resistant S. aureus and vancomycin-resistant Enterococcus (VRE). Only oritavancin and linezolid remained active against Enterococcus faecium isolates displaying an elevated daptomycin MIC (i.e., 2 to 4 mg/L). Proportions of methicillin-resistant S. aureus and vancomycin-resistant Enterococcus within the respective S. aureus and enterococcal populations decreased over this period.

Ejemplares similares